Table 1 Patient baseline characteristics and summary of prior and current treatments for localized, advanced, and castration-resistant prostate cancer.
Clinical variable | Full cohort | Carriers | Noncarriers | P value |
|---|---|---|---|---|
(n = 221) | (n = 27, 12.2%) | (n = 194, 87.8%) | ||
Median age at baseline, years (IQR) | 73.2 (68.5–78.5) | 76.1 (70.3–79.5) | 73.1 (68.3–78.2) | 0.32 |
Median baseline PSA, µg/L (IQR) | 28.6 (11.4–61.8) | 31.2 (10.8–118.8) | 26.8 (11.4–59.8) | 0.49 |
ECOG performance status ≥ 1, n (%) | 81 (36.7) | 10 (37.0) | 71 (36.6) | 1 |
Median baseline ALP, U/L (IQR) | 74.5 (58.8–127.8) | 102.5 (57.5–193.5) | 74 (59.0–118.8) | 0.23 |
Bone metastases present, n (%) | 181 (81.9) | 22 (81.5) | 159 (82.0) | 1 |
Visceral metastases present, n (%) | 10 (4.5) | 2 (7.4) | 8 (4.1) | 0.36 |
Radical treatments prior to mCRPC, n (%) | 0.62 | |||
Radical prostatectomy | 16 (7.2) | 2 (7.4) | 14 (7.2) | |
Radiation | 6 (2.7) | 1 (3.7) | 5 (2.6) | |
Radiation and endocrine | 23 (10.4) | 1 (3.7) | 22 (11.3) | |
None | 175 (79.2) | 23 (85.2) | 152 (78.4) | |
Other | 1 (0.5) | 0 | 1 (0.5) | |
Taxane treatment prior to mCRPC, n (%) | 65 (29.4) | 8 (29.6) | 57 (29.4) | 1 |
First systemic therapy for mCRPC, n (%) | 1 | |||
Enzalutamide | 195 (88.2) | 24 (88.9) | 171 (88.1) | |
Abiraterone | 23 (10.4) | 3 (11.1) | 20 (10.3) | |
Docetaxel | 3 (1.4) | 0 | 3 (1.5) | |
Median time, ADT to mCRPC, months (IQR) | 19.3 (11.9–38.3) | 12.7 (7.0–22.5) | 20.0 (12.7–39.0) | 0.03 |
Median time, 1st Line ARSI, months (IQR) | 10.6 (6.0–18.0) | 8.4 (6.5–12.0) | 10.8 (6.0–18.7) | 0.46 |
Dead, n (%) | 97 (43.9) | 14 (51.9) | 83 (42.8) | 0.41 |
